[Breaking] Genexine to Receive $3 Million (4.2 Billion Won) in Milestone Payment as NeoImmuneTech-Licensed 'GX-I7' Completes Phase 2 Trial
Genexine announced that it has achieved a milestone related to 'GX-I7', a technology out-licensed to NeoImmuneTech, and is set to receive a $3 million (approximately 4.2 billion won) technology fee. The milestone confirmed this time is the 'completion of the phase 2 clinical trial' among the detail
![[Breaking] Genexine to Receive $3 Million (4.2 Billion Won) in Milestone Payment as NeoImmuneTech-Licensed 'GX-I7' Completes Phase 2 Trial](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F581031%2F0c2a8f5a6d5bef88%2Foriginal.webp&w=1920&q=75)
Genexine announced that it has achieved a milestone related to 'GX-I7', a technology out-licensed to NeoImmuneTech, and is set to receive a $3 million (approximately 4.2 billion won) technology fee.
The milestone confirmed this time is the 'completion of the phase 2 clinical trial' among the detailed milestones. The technology fee amounts to more than 10% of Genexine's revenue based on 2025 figures.
The won conversion was calculated at approximately 4.2 billion won, based on the Seoul Foreign Exchange Brokerage midpoint rate (1,393 won per dollar) as of August 21. The date of occurrence, August 21, 2026, is the company's invoice issuance date.
Under the contract, Genexine plans to receive the technology fee within 30 days of the milestone achievement date. The company stated that if key contract terms change or disclosure obligations arise in the future, it will make disclosures without delay.
The company explained that if future clinical trials, approvals, or commercialization do not materialize, the technology transfer agreement may be terminated. However, even if the contract is terminated, there is no obligation to return milestone payments already received. It also added that this contract was not subject to disclosure, as the total contract amount stated in the agreement fell below 10% of the company's equity capital, the disclosure threshold at the time.
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] Cyberattack via Optimizely Exposes 178 Global Organizations... CNN, BBC, HSBC, and Ledger Also Affected](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F627874%2Ffc472b72a2596aa1%2Fvariants%2Fhero.webp&w=1920&q=75)


